The ubiquitin-proteasome system in HIV replication: potential targets for antiretroviral therapy - PubMed

Review

The ubiquitin-proteasome system in HIV replication: potential targets for antiretroviral therapy

Patricia P Klinger et al. Expert Rev Anti Infect Ther. 2005 Feb.

Abstract

Since the discovery of HIV approximately 20 years ago, more than 60 million individuals have been infected, and AIDS still remains one of the most devastating diseases humankind has ever faced. Unfortunately, there is little hope that an effective vaccine will be developed in the near future. Current antiretroviral treatment is based on drugs that either target the viral enzymes (protease and reverse transcriptase) or the attachment and entry of the virus. Although the introduction of highly active antiretroviral therapy in the mid-1990s has led to a profound reduction in HIV-related morbidity and mortality, the complete eradication of the virus from infected individuals has never been achieved. In addition, these antiviral drugs can induce serious adverse effects, particularly when administered in combination over prolonged treatment periods. A further drawback to these treatments is that with the high mutation rate of HIV, drug-resistant mutants are evolving, particularly when antiretroviral treatment only suppresses virus replication to marginal levels in latently infected cells making up the virus reservoirs in vivo. Cellular genes have much lower mutation rates, and drug-mediated modulation of specific cellular pathways represents an attractive antiviral strategy. Recent findings showing that proteasome inhibitors interfere with budding, maturation and infectivity of HIV have triggered intensive investigation of the hitherto unappreciated function of the ubiquitin-proteasome system in HIV replication. It was also observed that, like several other retroviruses, HIV-1 virions contain a small amount of mono-ubiquitinylated Gag proteins. Currently, two E3-type ubiquitin ligases, in addition to one E3-like protein, have been identified as regulators of HIV budding. These ligases might represent interesting targets for therapeutic intervention.

Similar articles

• Ubiquitin ligases as therapeutic targets in HIV-1 infection.

  Votteler J, Schubert U. Votteler J, et al. Expert Opin Ther Targets. 2008 Feb;12(2):131-43. doi: 10.1517/14728222.12.2.131. Expert Opin Ther Targets. 2008. PMID: 18208363 Review.

• Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

  Van Vaerenbergh K. Van Vaerenbergh K. Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Verh K Acad Geneeskd Belg. 2001. PMID: 11813503 Review.

• [Development of antituberculous drugs: current status and future prospects].

  Tomioka H, Namba K. Tomioka H, et al. Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.

• Inhibitors of Deubiquitinating Enzymes Block HIV-1 Replication and Augment the Presentation of Gag-Derived MHC-I Epitopes.

  Setz C, Friedrich M, Rauch P, Fraedrich K, Matthaei A, Traxdorf M, Schubert U. Setz C, et al. Viruses. 2017 Aug 12;9(8):222. doi: 10.3390/v9080222. Viruses. 2017. PMID: 28805676 Free PMC article.

• Molecular biological assessment methods and understanding the course of the HIV infection.

  Katzenstein TL. Katzenstein TL. APMIS Suppl. 2003;(114):1-37. APMIS Suppl. 2003. PMID: 14626050 Review.

Cited by

• The role of allostery in the ubiquitin-proteasome system.

  Liu J, Nussinov R. Liu J, et al. Crit Rev Biochem Mol Biol. 2013 Mar-Apr;48(2):89-97. doi: 10.3109/10409238.2012.742856. Epub 2012 Dec 13. Crit Rev Biochem Mol Biol. 2013. PMID: 23234564 Free PMC article. Review.

• Modular mimicry and engagement of the Hippo pathway by Marburg virus VP40: Implications for filovirus biology and budding.

  Han Z, Dash S, Sagum CA, Ruthel G, Jaladanki CK, Berry CT, Schwoerer MP, Harty NM, Freedman BD, Bedford MT, Fan H, Sidhu SS, Sudol M, Shtanko O, Harty RN. Han Z, et al. PLoS Pathog. 2020 Jan 6;16(1):e1008231. doi: 10.1371/journal.ppat.1008231. eCollection 2020 Jan. PLoS Pathog. 2020. PMID: 31905227 Free PMC article.

• The proteasome inhibitor Velcade enhances rather than reduces disease in mouse hepatitis coronavirus-infected mice.

  Raaben M, Grinwis GC, Rottier PJ, de Haan CA. Raaben M, et al. J Virol. 2010 Aug;84(15):7880-5. doi: 10.1128/JVI.00486-10. Epub 2010 May 19. J Virol. 2010. PMID: 20484516 Free PMC article.

• Pyrrolidine dithiocarbamate inhibits herpes simplex virus 1 and 2 replication, and its activity may be mediated through dysregulation of the ubiquitin-proteasome system.

  Qiu M, Chen Y, Cheng L, Chu Y, Song HY, Wu ZW. Qiu M, et al. J Virol. 2013 Aug;87(15):8675-86. doi: 10.1128/JVI.00869-13. Epub 2013 Jun 5. J Virol. 2013. PMID: 23740985 Free PMC article.

• Host protein Ku70 binds and protects HIV-1 integrase from proteasomal degradation and is required for HIV replication.

  Zheng Y, Ao Z, Wang B, Jayappa KD, Yao X. Zheng Y, et al. J Biol Chem. 2011 May 20;286(20):17722-35. doi: 10.1074/jbc.M110.184739. Epub 2011 Mar 29. J Biol Chem. 2011. PMID: 21454661 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database